65,437 trials
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis — -43.8; -70.1; -4.3 percent change — p=<0.0001
Critical Illness · Sleep Deprivation · Respiratory Failure
Primary: Circadian Timing — 3.6; -2.4 hours — p=0.37
Advanced or Metastatic Hepatocellular Cancer · Advanced or Metastatic Ovarian Cancer · Metastatic Renal Cell Cancer
Primary: Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All…
Acne Vulgaris
Primary: Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12 — -10.7; -15.1 lesion count — p=< 0.0001
Weight Gain
Primary: Weight Changes From Baseline Over Follow-up. — 0.26; -0.56; -2.37 kilograms — p=<0.05
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Postoperative Pain · Carpal Tunnel Release · Distal Radius Fracture
Primary: Postoperative Pain (Pain Scores From 0-10 Scale) — 2.0; 2.9; 2.7; 2.0 units on a scale
Non-alcoholic Steatohepatitis · Non-alcoholic Fatty Liver Disease
Primary: Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) — 6.9; 9.6; 7.0 units on a scale — p=0.474
Urea Cycle Disorders
Primary: Number of Participants With at Least One Adverse Event — 34; 40 Participants
Neurotoxicity · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Change in Average Daily Pain Score as Measured Using a Pain Intensity Rating (NRS) — -0.3; -0.5 units on a scale — p=0.56
Acne Vulgaris
Primary: Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) — 94; 94 participants
Stroke · Hemiparesis
Primary: Change in Baseline Step Length Symmetry. That is, Whether the Steps With Right and Left Legs Are the Same Length. — 0.001; -0.078; -0.045; 0.144 ratio
Clostridium Difficile Infection
Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 83.8; 85.2 Percentage of participants
Spinal Muscular Atrophy (SMA)
Primary: Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) — 36.06; 88.47; 40.54; 89.44 scores on a scale
Labor Pain
Primary: Number of Subjects With Success Rate at 15 Minutes Post-epidural Bolus Injection — 31; 38 Participants — p=0.38